Pyridinyl derivatives for the treatment of depression

Details Pyridinyl derivatives for the treatment of depression Pyridinyl derivatives for the treatment of depression

2006-04-18

2006-04-18

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S352000, C546S293000, C546S312000, C546S297000

Reexamination Certificate

active

07030145

ABSTRACT:
The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”)useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

REFERENCES:
patent: 2003/0096817 (2003-05-01), Green et al.
patent: WO 95/10506 (1995-04-01), None
patent: WO 95/33750 (1995-12-01), None
patent: WO 97/45421 (1997-12-01), None
patent: WO 98/03510 (1998-01-01), None
patent: WO 99/51608 (1999-10-01), None
patent: WO 00/53604 (2000-09-01), None
patent: WO 00/59888 (2000-10-01), None
patent: WO 01/53263 (2001-07-01), None
patent: WO 01/62718 (2001-08-01), None
patent: WO 01/68614 (2001-09-01), None
patent: WO 02/06242 (2002-01-01), None
Kehne, Current Drug Targets: CNS & Neurological Disorders, vol. 1(5), pp. 467-493, 2002.
Dunn, A.J., et al., “Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?” Brain Research Reviews, 15, 1990, pp. 71-100.
Gulyas, J, et al., “Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor,” Proc. Natl. Acad. Sci. USA, vol. 92, Nov. 1995, pp. 10575-10579.
McCarthy, et al., “Recent Advances with the CRF1 Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications,” Current Pharmaceutical Design, 1999, 5, pp. 289-315.
Holsboer, F., “The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety,” Journal of Psychiatric Research, 33, 1999, pp. 181-214.
Banki, C.M., et al., “CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse,” European Neuropsychopharmacology, 2, 1992, pp. 107-113.
Webster, E.L., et al., “Corticotropin-Releasing Hormone and Inflammation,” Annals New York Academy of Sciences, 840, 1998, pp. 21-32.
Gilligan, P.J., et al., “Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents,” Journal of Medicinal Chemistry, vol. 43, No. 9, May 4, 2000, pp. 1641-1660.
McCarthy, J.R., et al., “Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents,” Annual Reports in Medicinal Chemistry, vol. 34, 1999, pp. 11-20.

Affiliated with

Also associated with

Rating

Pyridinyl derivatives for the treatment of depression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridinyl derivatives for the treatment of depression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridinyl derivatives for the treatment of depression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3574329